If you are exposed to a needle stick, splash in the eye, or other high-risk exposure:
1. Immediately dispose of sharps
safely, if necessary.
2. Explain to the patient that you will now transfer their care
to another clinic worker, while you care for your
injury, and ask them to wait for this transfer.
3. Notify your replacement clinic worker that you are activating the Needlestick Protocol:
Both you and the patient will be tested
for communicable diseases (i.e., receive free HIV and hepatitis
testing through the HIV Al iance/Needle Exchange). This is NOT optional.
The clinic worker must obtain and document the patient's risk status
(remote and recent injection or
needle use of any kind; blood transfusions, with year; known disease history).
Before the patient leaves the clinic, their correct contact information
must be documented, for fol ow-
up of this testing.
Before the patient leaves the clinic, they must be given written contact information for the HIV Al iance/ Needle Exchange, and instructed to visit them for free testing:
HIV Alliance/Needle Exchange phone, 541-342-5088
. Location, 1966 Garden Avenue, Eugene.
(Needle Exchange has mobile sites throughout the week - cal for details.)
Alternatively, the patient may visit their personal physician; document this physician's contact information before the patient leaves the clinic, for followup.
Notify the patient that IF official documentation of recent negative HIV and hepatitis B/C testing
provided by medical authorities, no new testing or treatment are necessary.
4. Clean the wound
thoroughly with alcohol-based hand sanitizer (containing at least 60% alcohol, which kil s
HIV, HBV, and HCV), or rinse eye/s very thoroughly with fresh water or sterile saline solution.
Do not squeeze a puncture wound - it causes microtrauma and swelling, and doesn't help.
the date, time, route of exposure, and patient and staff risk factors for blood-borne diseases.
Deliver this information to the clinic manager.
The clinic manager is to open a file to document:
1. The staff member's exposure report2. Patient's and staffer's test results (rapid HIV, HBsAg, anti-HBs antibodies, anti-HCV)3. Patient's and staffer's treatment plans (post-exposure prophylaxis/PEP and fol owup care,
including emotional support and education)
Do NOT leave the clinic yourself, without a prescription for post-exposure prophylaxis
preventive medication) that you can fill and take within 2 hours of exposure, OR SOONER. See below for
Do NOT leave the clinic yourself, without documenting the injury/exposure, notifying the clinic manager, and planning your testing and treatment regimen.
6. Immediate testing
The patient should be rapid-tested for HIV
(results within an hour), with a positive result fol owed by a
Western blot for confirmation. Negative rapid tests do NOT require further testing.
The patient should be tested for hepatitis
(HBV surface antigen, HBsAg, and anti-HCV antibodies)
If the patient's rapid HIV is negative, the staffer does NOT need HIV testing, other than routinely, or treatment (PEP).
If the patient is HIV positive, the exposed staffer should be tested for HIV immediately and at 6 and 12 weeks, and 6 months after exposure. Most people seroconvert in the first 3 months, if at al .
The staffer should be tested for hepatitis on the basis of the patient's results. See below for details.
7. HIV post-exposure prophylactic (PEP) treatment:
If the patient's HIV status is unknown, take immediate post-exposure prophylaxis medication
(PEP) while waiting for the patient's rapid HIV test results.
If the patient is thought to be very low risk, you can wait 1-2 hours
before starting PEP medication
while awaiting rapid HIV testing. If no results within 2 hours, start PEP immediately. (You can stop the
PEP if the patient later turns out to be HIV negative.)
If the patient is known to be HIV positive, start PEP immediately, and plan to continue it for 4 weeks.
HIV-PEP is most effective if started within 1-2 hours of exposure, or sooner.
8. What drugs for HIV-PEP?
Cal the National Clinicians' Postexposure Prophylaxis Hotline (PEPline, 888-448-4911)
Preferred: Truvada (tenofovir/emtricitabine, 300/200 mg daily) plus Isentress (raltegravir, 400 mg twice daily)
Alternative: Truvada (tenofovir/emtricitabine, 300/200 mg daily) plus Reyataz (atazanavir, 300 mg daily) and Norvir (ritonanvir, 100 mg daily),
OR Truvada (tenofovir/emtricitabine, 300/200 mg daily) plus Prezista (darunavir, 800 mg daily) and Norvir (ritonanvir, 100 mg daily) with food.
Additional possible regimens: Atripla (efavirenz/tenofovir/emtricitabine, 600/300/200 mg daily),
OR Truvada (tenofovir/emtricitabine, 300/200 mg daily) plus Kaletra (lopinavir/ritonavir, 400/100 mg twice daily),
OR Zerit (stavudine, 30 mg twice daily) and Epivir (lamivudine, 150 mg twice daily) in place of tenfovir/emtricitabine in the above regimens if the latter is contraindicated.
For pregnant workers: Combivir (zidovudine-lamivudine, 150/300 twice daily) and Kaletra (lopinavir/ritonavir, 400/100 mg twice daily). Efavirenz should not be used in women who are or might be pregnant.
Drugs that should NOT be used are abacavir (Ziagen) and nevirapine (Viramune), which may cause severe and sometimes life-threatening side effects, especial y during the first few weeks of exposure.
(http://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/ Updated 3/28/2012.)
Others on the above list are not found from this pharmacy.
Plan to take HIV-PEP medication for 4 weeks
or longer. If the patient is found to be HIV-negative, you can stop
the PEP medication.
9. Hepatitis B
testing and treatment:
If the patient is HBV negative, you might not need further testing.
If you have been vaccinated against hepatitis B, get tested to verify that you are immune.
If immune, you wil have positive anti-HBs (antibodies to hepatits B surface antigen, which is used to make the vaccine). You might not need further testing.
If you are not immune, and the patient is positive, (had a poor response, or the vaccine wore off), you will need to be treated as though unvaccinated.
HBV-PEP consists of HBIG ("Hepagam," hepatitis B immunoglobulin, 0.06mg/kg, repeated in one month if not HBV immune) and/or hepatitis B vaccination (a 3-shot series).
10. Hepatitis C
testing and treatment:
If the patient is HCV negative, you don't need further testing for HCV, although CDC recommends that adults born in 1945-1965, those who got blood before 1992, and many others with "mild" risk factors, get screened routinely for anti-HCV antibodies.
If the patient is HCV positive, get fol ow-up testing for HCV RNA by PCR 4-6 weeks after exposure.
Continue fol ow-up testing for anti-HCV antibodies by ELISA, HCV RNA, and liver enzymes (ALT and AST) 4-6 months after exposure.
There is currently no PEP or vaccine for hepatitis C. Immunoglobulin (HCIG) and antiviral agents are NOT recommended. Consult your personal physician or a liver specialist for advice.
For latest CDC data, see http://www.cdc.gov/hai/
Completed by ____________________________________________ Date ____/____/________
Exposed staffer name/DOB ________________________________________________________
Patient contact info ______________________________________________________________
Patient risk status (hx blood borne illness, IVDU, transfusion, MSM, etc.) ____________________
Time, date, and route of exposure ___________________________________________________
Patient had rapid HIV test* Result negative > no further HIV testing needed
Result positive > sent for Western blot confirmation Result positive > staffer tested for HIV > staffer to doctor for management
Patient documented recent negative for HBV (date ____/____/________), copy in chart Patient documented recent negative for HCV (date ____/____/________), copy in chart
Patient tested for HBV/HCV* HBV-vaccinated staffer tested for immunity, found immune (positive anti-HBs Abs)
HBV-vaccinated staffer tested for immunity, found not immune (negative anti-HBs Abs) Patient HBV-positive (HBsAg positive) > staffer to doctor for testing and HBV-PEP
Patient HCV-positive (anti-HCV Abs positive) > staffer to doctor for testing and management
Financial assistance provided for rx Staffer started PEP within 2 hrs of exposure
PEP discontinued when patient documented HIV-negative
*HIV Al iance, 541-342-5088, 1966 Garden Avenue, Eugene. Mon-Tues 5-7 pm; Wed 6-8 pm; Fri 3-5 pm.
BIOLOGY 230 Review Sheets 1. Label the following as atoms, cations, anions, or molecules. ______________ Mg+2______________ H2O______________ O2______________ Na______________ Cl-______________ Ca+22. In saline (salty water), what is the solute and what is the solvent?3. Be able to recognize biomolecules indicating their major molecular group and specific type. 4. Calcium atoms have two ele
DEVELOPMENT OF A CLINICAL DEHYDRATION SCALE FOR USE INJEREMY N. FRIEDMAN, MBBCH, FRCPC, RAN D. GOLDMAN, MD, RAJENDU SRIVASTAVA, MD, FRCPC, MPH, ANDTo develop a clinical dehydration scale for use in children <3 years of age. Prospective cohort study of children between 1 and 36 months of age who presented to a tertiary pediatricemergency department (ED) with gastroenteritis. Children were we